Meet Neuland at CPHI India 2026 | Hall 2, Booth 2D38 | Yashobhoomi Convention Centre, New Delhi | 24-26 November 2026 Schedule a Meeting
Meet Neuland at CPHI India 2026 | Hall 2, Booth 2D38 | Yashobhoomi Convention Centre, New Delhi | 24-26 November 2026 Schedule a Meeting
Turning a new laboratory discovery into a successful medicine involves many complex steps, and one crucial step is process development and scale-up.
This is the phase where a promising molecule’s journey shifts from small-scale experiments to reproducible large-scale manufacturing – all while ensuring that every batch meets strict quality, safety, and efficacy standards.
For pharmaceutical companies, this transition is challenging; for a Contract Development and Manufacturing Organization (CDMO) like us, it’s where we excel. We bridge the gap between drug research and full-scale production by focusing on robust process development and methodical scale-up.
In this guide, we outline how CDMOs manage process development and scale-up from early development through commercial manufacturing, ensuring risks are mitigated, costs are controlled, and quality and compliance are built in.
Process development in pharmaceutical industry settings involves creating efficient, cost-effective, and regulatory-compliant production methods while maintaining high product quality. It includes selecting raw materials, setting up equipment, optimizing reaction steps, and establishing in-process controls.
In essence, it turns a lab concept into a reproducible, scalable process by ensuring each step is efficient, reliable, and can be scaled up without issues. This is a multi-disciplinary effort: chemists, engineers, and manufacturing experts work together to test conditions and implement solutions that will work on a larger scale.
The result of effective chemistry and process development consistently produces the Active Pharmaceutical Ingredient (API) and final drug product at the required quality and yield. Laying this groundwork not only ensures product consistency but also improves efficiency – often reducing waste, boosting yields, and speeding time-to-market.
It also ensures the drug’s critical quality attributes (CQAs) are met batch after batch by tightly controlling key parameters.
Process development and scale-up are about ensuring quality, consistency, and compliance across every stage. Each phase builds upon the last to reduce risks and optimize performance for commercial manufacturing.
API scale-up from laboratory to manufacturing scale presents a host of challenges. Small-scale processes often need adjustments to work on a larger scale. Factors such as mixing efficiency, heat removal, and reaction kinetics can change when volumes increase, sometimes leading to lower yields or new impurities.
Such issues underscore why process optimization strategies are essential. Without proactive optimization, companies risk batch failures, quality deviations, or costly production delays.
To mitigate these risks, developers employ several techniques during process development and scale-up. One approach is to apply Quality by Design (QbD) principles – using design of experiments (DoE) to identify critical process parameters and define their acceptable ranges, ensuring the process stays robust as it scales.
Process safety is also a crucial aspect of scale-up. Certain steps that are harmless in the lab may pose hazards at the production scale, for example, generating much more heat or pressure.
In one case, our team eliminated a hazardous reagent and improved the overall process yields by 3-fold during scale-up by modifying the process chemistry. This exemplifies how smart development work can improve both safety and efficiency, reducing manufacturing risks and costs.
A capable CDMO plays a pivotal role in ensuring seamless process development and scale-up for drug sponsors. As a project moves from research into development, partnering with a CDMO brings specialized expertise, infrastructure, and experience to bear.
One major advantage of leveraging CDMO services is risk reduction and speed. For companies without extensive in-house development facilities, a CDMO’s process development expertise and ready infrastructure fill the gap.
By entrusting CDMO process development experts with scale-up, drug innovators can focus on their core discovery and clinical efforts, confident that the transition to manufacturing is in capable hands.
Effective process development and scale-up are the cornerstones of turning a new molecule into a viable treatment.
These principles form the core of how we operate at Neuland Labs. In all our pharma process development projects, we emphasize these principles. With over 40 years of experience in developing complex small molecules and peptides, we have guided countless projects from early development through successful commercial manufacturing.
Achieving success in this domain requires both scientific rigor and practical manufacturing know-how – and this is how we do it at Neuland. We combine deep expertise, state-of-the-art facilities, and an unwavering focus on quality and efficiency at every step.
By working closely with our partners and leaving no detail overlooked, we ensure that scale-up, tech transfer, and production are executed right.
Check out how Neuland supports process development and scale-up, which leads to life-changing medicines reaching patients faster and more reliably.
Process optimization during scale-up helps refine reaction conditions and control parameters to ensure consistency, efficiency, and regulatory compliance—critical elements within a process development and scale-up strategy.
CDMOs should ideally be engaged from preclinical or early development stages to streamline process development and scale-up, ensure regulatory foresight, and build a scalable, phase-appropriate route to commercialization.
If scale-up isn’t planned properly, issues like impurity formation, equipment incompatibility, or regulatory delays can arise—affecting both cost and timelines of the process development and scale-up program.
Yes, scale-up success can vary significantly based on the API’s chemical complexity, sensitivity, and synthesis route. More complex molecules often demand customized engineering controls and analytical support.
